Role
Chief Investigator
Description
Our goal is to accelerate the development of SARS-CoV-2 neutralising antibody, BD-218, towards a first-in-human Phase I toxicity and dose-escalation trial at Royal Prince Alfred Hospital, NSW and The Alfred Hospital, Victoria in mid-2020.
Date
01 Jan 2021 - 31 Dec 2021
Project Type
GRANT
Keywords
N/A
Funding Body
Aimmune Therapeutics
Amount
50000
Project Team
N/A